Actions undertaken by the industry to alleviate the negative impact of rising energy prices are presented in a second paper in this two-part series.”
“We sought to determine the impact of esophagectomy on survival in patients with adenocarcinoma of the esophagus cancer after chemoradiotherapy (CRT). A database of esophageal cancer was queried for nonmetastatic patients with adenocarcinoma treated between

2000 and 2011 with CRT. Overall survival (OS) and recurrence-free survival (RFS) curves were calculated according to the Kaplan-Meier method and log-rank analysis. Multivariate analysis was performed by the Cox proportional hazard model. We identified 154 patients (60 without surgery; 94 with surgery) who were included in the analysis. The only differences between the 2 groups selleck products were more advanced disease stage, improved performance status, and BIX 01294 chemical structure younger age in the surgery group. Patients undergoing surgery had significantly higher survival. Median and 5-year OS for surgical patients were 4.1 years and 43.6 %, versus 1.9 years and 35.6 % for nonsurgical patients (p = 0.007). Multivariate analysis for OS and RFS revealed that factors associated with increased survival were surgical resection, tumor length smaller than 5 cm, male gender, and lower stage. Age, tumor location, radiation dose/technique, and induction

chemotherapy were not prognostic. There 4EGI-1 in vitro was a trend toward improved survival on univariate analysis (p = 0.10) and multivariate analysis (p = 0.063) for surgical patients compared to nonsurgical patients who were healthy enough for surgery before CRT (n = 38), and no difference in OS in nonsurgical patients healthy enough for surgery after CRT (n = 22). Esophagectomy after CRT is associated with improved survival in patients with adenocarcinoma after CRT. Trimodal therapy should continue to remain the standard of care for esophageal adenocarcinoma.”
“Background and Aim: Severe alcoholic hepatitis (SAH)

is an inflammatory response with multiple morbidity factors like leucocytosis, hepatomegaly, renal failure, hepatic encephalopathy, endotoxemia, and a high mortality rate. Identifying therapeutic interventions that can improve prognosis is the goal of research.\n\nMethods: Questionnaires were sent to 1234 medical institutions asking for information on patients with SAH during 2004 to 2008, including patients’ demography, disease profile and the therapeutic interventions patients had received during hospitalization.\n\nResults: Forty-five hospitals had treated SAH patients, and provided full demographic data on 98 patients. Forty-eight patients had received no treatment, 12 patients had received granulocytes/monocytes apheresis (GMA) to deplete elevated myeloid lineage leucocytes, the rest had received one or more of the following treatments, corticosteroids, plasma exchange (PE) and hemodialysis (HD).